A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

NCT05200364 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

58

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated Early

Conditions

Ovarian Cancer
Ovarian Carcinoma
Ovary Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: STRO-002
DRUG: Bevacizumab

Sponsor

Sutro Biopharma, Inc.